TY - JOUR
T1 - Genetic Risk Score for Intracranial Aneurysms
T2 - Prediction of Subarachnoid Hemorrhage and Role in Clinical Heterogeneity
AU - HUNT All In Stroke
AU - CADISP group
AU - International Consortium for Blood Pressure
AU - The International Headache Genetics Consortium
AU - International Stroke Genetics Consortium (ISGC)
AU - Bakker, Mark K.
AU - Kanning, Jos P.
AU - Abraham, Gad
AU - Martinsen, Amy E.
AU - Winsvold, Bendik S.
AU - Zwart, John Anker
AU - Bourcier, Romain
AU - Sawada, Tomonobu
AU - Koido, Masaru
AU - Kamatani, Yoichiro
AU - Morel, Sandrine
AU - Amouyel, Philippe
AU - Debette, Stéphanie
AU - Bijlenga, Philippe
AU - Zhou, Wei
AU - Metso, Antti J.
AU - Metso, Tiina
AU - Tatlisumak, Turgut
AU - Havulinna, Aki S.
AU - Jousilahti, Pekka
AU - Koskinen, Seppo
AU - Kristiansson, Kati
AU - Niiranen, Teemu
AU - Palotie, Aarno
AU - Perola, Markus
AU - Ripatti, Samuli
AU - Sarin, Antti Pekka
AU - Tuomilehto, Jaakko
AU - Anttila, Verneri
AU - Palta, Priit
AU - Muona, Mikko
AU - Wedenoja, Juho
AU - Färkkilä, Markus
AU - Artto, Ville
AU - Kaunisto, Mari
AU - Vepsäläinen, Salli
AU - Kurki, Mitja I.
AU - Kals, Mart
AU - Pärn, Kalle
AU - Hämäläinen, Eija
AU - Eriksson, Johan G.
AU - Heikkilä, Kauko
AU - Kaprio, Jaakko
AU - Wessman, Maija
AU - Daly, Mark J.
AU - Neale, Benjamin M.
AU - Jääskeläinen, Juha E.
AU - Lindgren, Antti
AU - Niemelä, Mika
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Background: Recently, common genetic risk factors for intracranial aneurysm (IA) and aneurysmal subarachnoid hemorrhage (ASAH) were found to explain a large amount of disease heritability and therefore have potential to be used for genetic risk prediction. We constructed a genetic risk score to (1) predict ASAH incidence and IA presence (combined set of unruptured IA and ASAH) and (2) assess its association with patient characteristics. Methods: A genetic risk score incorporating genetic association data for IA and 17 traits related to IA (so-called metaGRS) was created using 1161 IA cases and 407 392 controls from the UK Biobank population study. The metaGRS was validated in combination with risk factors blood pressure, sex, and smoking in 828 IA cases and 68 568 controls from the Nordic HUNT population study. Furthermore, we assessed association between the metaGRS and patient characteristics in a cohort of 5560 IA patients. Results: Per SD increase of metaGRS, the hazard ratio for ASAH incidence was 1.34 (95% CI, 1.20-1.51) and the odds ratio for IA presence 1.09 (95% CI, 1.01-1.18). Upon including the metaGRS on top of clinical risk factors, the concordance index to predict ASAH hazard increased from 0.63 (95% CI, 0.59-0.67) to 0.65 (95% CI, 0.62-0.69), while prediction of IA presence did not improve. The metaGRS was statistically significantly associated with age at ASAH (β=-4.82×10-3per year [95% CI, -6.49×10-3to -3.14×10-3]; P=1.82×10-8), and location of IA at the internal carotid artery (odds ratio=0.92 [95% CI, 0.86-0.98]; P=0.0041). Conclusions: The metaGRS was predictive of ASAH incidence, although with limited added value over clinical risk factors. The metaGRS was not predictive of IA presence. Therefore, we do not recommend using this metaGRS in daily clinical care. Genetic risk does partly explain the clinical heterogeneity of IA warranting prioritization of clinical heterogeneity in future genetic prediction studies of IA and ASAH.
AB - Background: Recently, common genetic risk factors for intracranial aneurysm (IA) and aneurysmal subarachnoid hemorrhage (ASAH) were found to explain a large amount of disease heritability and therefore have potential to be used for genetic risk prediction. We constructed a genetic risk score to (1) predict ASAH incidence and IA presence (combined set of unruptured IA and ASAH) and (2) assess its association with patient characteristics. Methods: A genetic risk score incorporating genetic association data for IA and 17 traits related to IA (so-called metaGRS) was created using 1161 IA cases and 407 392 controls from the UK Biobank population study. The metaGRS was validated in combination with risk factors blood pressure, sex, and smoking in 828 IA cases and 68 568 controls from the Nordic HUNT population study. Furthermore, we assessed association between the metaGRS and patient characteristics in a cohort of 5560 IA patients. Results: Per SD increase of metaGRS, the hazard ratio for ASAH incidence was 1.34 (95% CI, 1.20-1.51) and the odds ratio for IA presence 1.09 (95% CI, 1.01-1.18). Upon including the metaGRS on top of clinical risk factors, the concordance index to predict ASAH hazard increased from 0.63 (95% CI, 0.59-0.67) to 0.65 (95% CI, 0.62-0.69), while prediction of IA presence did not improve. The metaGRS was statistically significantly associated with age at ASAH (β=-4.82×10-3per year [95% CI, -6.49×10-3to -3.14×10-3]; P=1.82×10-8), and location of IA at the internal carotid artery (odds ratio=0.92 [95% CI, 0.86-0.98]; P=0.0041). Conclusions: The metaGRS was predictive of ASAH incidence, although with limited added value over clinical risk factors. The metaGRS was not predictive of IA presence. Therefore, we do not recommend using this metaGRS in daily clinical care. Genetic risk does partly explain the clinical heterogeneity of IA warranting prioritization of clinical heterogeneity in future genetic prediction studies of IA and ASAH.
KW - aneurysmal subarachnoid hemorrhage
KW - genetic heterogeneity
KW - genetics
KW - intracranial aneurysm
KW - risk assessment
KW - 3112 Neurosciences
KW - 1184 Genetics, developmental biology, physiology
U2 - 10.1161/STROKEAHA.122.040715
DO - 10.1161/STROKEAHA.122.040715
M3 - Article
SN - 0039-2499
VL - 54
SP - 810
EP - 818
JO - Stroke
JF - Stroke
IS - 3
ER -